Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors

• Status: Recruiting
• Trial end date: 2026-07-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluate the safety and tolerability of RMC-9805 in adults with KRAS G12D-mutant solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Revolution Medicines, Inc.

Criteria

Inclusion Criteria:

• Pathologically documented, locally advanced or metastatic solid tumor malignancy with KRASG12D-mutations identified through deoxyribonucleic acid (DNA) sequencing or polymerase chain reaction (PCR) test

• Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage

• ECOG performance status 0 or 1

• Adequate organ function

Exclusion Criteria:

• Primary central nervous system (CNS) tumors

• Known or suspected leptomeningeal or active brain metastases or spinal cord compression

• Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication

• Participant was previously treated with an investigational KRASG12D inhibitor or had prior therapy with any direct RAS-targeted therapy (eg, degraders and inhibitors)

Other inclusion/exclusion criteria may apply.